These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26269439)

  • 1. [The impact of glycosylated hemoglobin target value in treatment guidelines on glycemic control of type 2 diabetic in Chinese cities].
    Gu W; Ji L; Guo X; Lu J
    Zhonghua Nei Ke Za Zhi; 2015 Mar; 54(3):193-6. PubMed ID: 26269439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.
    Vichayanrat A; Matawaran BJ; Wibudi A; Ferdous HS; Aamir AH; Aggarwal SK; Bajpai S
    J Diabetes; 2013 Sep; 5(3):309-18. PubMed ID: 23462227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic treatment patterns in a medicare advantage population in the United States.
    Slabaugh SL; Xu Y; Stacy JN; Baltz JC; Meah YA; Lian J; Moretz DC; Bouchard JR
    Drugs Aging; 2015 Feb; 32(2):169-78. PubMed ID: 25573537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China.
    Zhang L; Ji L; Guo L; Lu J; Tian H; Zhu D; Xing X; Weng JP; Jia W
    Diabetes Technol Ther; 2015 Nov; 17(11):816-24. PubMed ID: 26448574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 13. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N; Watada H; Murai M; Kagimura T; Gong Y; Patel S; Woerle HJ
    Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.
    Lin SD; Tsai ST; Tu ST; Su CC; Chen JF; Lu CH; Wang CH; Yu NC; Hsu SR; Hsieh MC
    Prim Care Diabetes; 2015 Apr; 9(2):135-41. PubMed ID: 25266893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.